Novavax is expanding its manufacturing capacity for its COVID-19 vaccine candidate by acquiring a manufacturer in the Czech Republic.

The $167 million acquisition of Praha Vaccines is expected to provide an annual capacity of more than 1 billion doses of antigen for Novavax’s vaccine candidate starting in 2021.

Praha Vaccines is part of the India-based Poonawalla Group that includes the Serum Institute of India, a manufacturer of pediatric vaccines.